Avet Company Profile
What is the competitive landscape for AVET
AVET has forty-one approved drugs.
Drugs and US Patents for Avet
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avet Lifesciences | RIFAMPIN | rifampin | INJECTABLE;INJECTION | 204101-001 | Aug 18, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Avet Lifesciences | MELPHALAN HYDROCHLORIDE | melphalan hydrochloride | INJECTABLE;INJECTION | 206523-001 | Oct 29, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Avet Lifesciences | ACARBOSE | acarbose | TABLET;ORAL | 202271-002 | Feb 7, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

